Pasithea Therapeutics Corp. (KTTA)
Company Description
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases.
It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers.
Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications.
The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia.
Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Country | United States |
Founded | 2020 |
IPO Date | Sep 15, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 15 |
CEO | Dr. Tiago Reis Marques M.D., Ph.D. |
Contact Details
Address: 2110 Narcissus Ct Venice, California 90291 United States | |
Phone | (818) 422-6172 |
Website | pasithea.com |
Stock Details
Ticker Symbol | KTTA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $5.00 |
CIK Code | 0001841330 |
CUSIP Number | 70261F103 |
ISIN Number | US70261F2020 |
Employer ID | 85-1591963 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder, MD and Executive Chairman |
Dr. Tiago Reis Marques M.D., Ph.D. | Chief Executive Officer and Director |
Daniel H. Schneiderman | Chief Financial Officer |
Dr. Yassine Bendiabdallah Ph.D. | Chief Operating Officer and Head of UK Clinics |
Dr. Graeme Currie Ph.D. | Chief Development Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 18, 2024 | 8-K | Current Report |
Jan 2, 2024 | 8-K | Current Report |
Dec 28, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Dec 28, 2023 | 8-K | Current Report |
Dec 19, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Dec 19, 2023 | 8-K | Current Report |
Nov 29, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Nov 13, 2023 | 10-Q | Quarterly Report |
Oct 26, 2023 | ARS | Filing |
Oct 26, 2023 | DEF 14A | Other definitive proxy statements |